top of page
Search

Echo IQ – Mayo Clinic Agreement Expands Commercial Pathway for EchoSolv HF After FDA Clearance

Echo IQ Ltd (ASX: EIQ) has expanded its agreement with Mayo Clinic to enable the potential resale and distribution of its heart failure decision support solution, EchoSolv HF, following FDA clearance.

I have liked the Echo IQ story from the first time I was introduced to it. The business is operating in a space where clinical validation, regulatory approval, and commercial deployment must align before revenue can be realised.

In my humble opinion, acceptance by Mayo is a transition from validation to potential commercialisation through a recognised US healthcare partner.

The agreement with Mayo Clinic introduces a defined pathway for distribution, contingent on FDA clearance, which is a key step in moving from technology development into the healthcare system.

Introduction – Echo IQ's Positioned for Commercial Deployment Through Mayo Clinic Platform

The expanded agreement allows EchoSolv HF to be deployed through the Mayo Clinic Platform – Solutions Studio Program, providing access to Mayo Clinic hospitals, its health system network, and more than 80 external partner hospitals.

The revised terms include improved commercial arrangements and an automatic extension mechanism that could extend the partnership to six years.

This development follows a completed validation study and the submission of a 510(k) application to the US FDA, with the product currently under regulatory review.

The Business of Echo IQ Limited

Echo IQ Limited is an AI-driven medical technology company focused on improving clinical decision-making in cardiology through proprietary software solutions.

The company’s core product, EchoSolv HF, is designed to assist in identifying heart failure using echocardiographic data. The business model is based on integrating software into existing hospital workflows and scaling distribution through established healthcare networks.

The company is currently in the regulatory phase, with commercial deployment dependent on FDA clearance.

Highlights – Expanded Commercial Pathway via Mayo Clinic Platform

  • Expanded agreement enables Mayo Clinic to resell and distribute EchoSolv HF following FDA clearance.

  • Deployment planned through the Mayo Clinic Platform – Solutions Studio Program, providing access to Mayo hospitals, health systems, and over 80 external partner hospitals.

  • Revised agreement includes improved commercial terms and an automatic extension, potentially extending the partnership to six years.

  • Platform-based distribution provides a defined pathway to scale adoption and potential revenue generation.

  • Validation study demonstrated sensitivity of 99.5% and specificity of 91.1% for heart failure detection (not yet FDA reviewed).

  • FDA 510(k) application submitted, currently under review.

  • US market context includes ~6.7 million diagnosed heart failure patients and ~2 million undiagnosed cases.

  • Approximately 16 million echocardiograms are performed annually in the US, with around 8 million containing heart failure-relevant findings.

Management Commentary

Echo IQ's Chief Executive Officer, Dustin Haines, stated that the expanded agreement represents a key milestone as the company approaches FDA clearance and potential commercial deployment.

He noted that the revised agreement provides a scalable pathway to market through the Mayo Clinic Platform and access to a broader healthcare ecosystem.

The company remains focused on progressing the FDA review process while preparing for commercial rollout and expanding its US healthcare partnerships.

Near-term Milestones to Watch

  • Outcome of FDA 510(k) review process for EchoSolv HF

  • Potential FDA clearance enabling commercial deployment

  • Initial deployment through Mayo Clinic Platform

  • Conversion of hospital access into revenue-generating installations

  • Expansion of US healthcare network partnerships


Previous Samso News Coverage – An Investor Lens

Samso has previously covered developments related to Echo IQ Limited (ASX: EIQ) and some recent articles have include:






Samso Concluding Comments

Without a full understanding of the business infrastructure of Echo IQ, this announcement, should read really well for shareholders. The share price is telling the market that this is welcomed news, and I would assume that this is going to continue to end well.

Figure 1: The share price chart for Echo IQ Limited as of the 23rd March 2026. (source: Echo IQ Limited).

Figure 1: The share price chart for Echo IQ Limited as of the 23rd March 2026. (source: Echo IQ Limited).

In contrast to the mineral resources sector, recognition from a major company like the Mayo Clinic serves as a testament to quality. Therefore, it stands to reason that the market acceptance aspect of the business is likely to endure.

The inclusion of the Mayo Clinic Platform provides access to a network of hospitals and healthcare providers. This creates a structure for scaling deployment without requiring the company to build its own distribution network.

The validation study results indicate strong diagnostic performance, but these results remain subject to FDA review. The regulatory process remains the key step before any commercial activity can begin.

The market context shows a large number of echocardiographic studies and a gap in accurate diagnosis. The company’s strategy is based on integrating its software into existing workflows within this environment and I think this extra step is what large organisations need. It is a tool for streamlining the flow of work and that means cost savings and output efficiency.

The Samso Way – Seek the Research


Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.

 

Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.


Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms: 



There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.


Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.

The Samso Philosophy:

Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.

In Life, there is no such thing as a Free Lunch.

Never bite off more than you can chew is my parting comment.

Happy Investing, and the only four-letter word you need to know is DYOR. 

To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiative for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.


Disclaimer

The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.



Share to Grow: Your Bonus


Samso has just released an eBook: How to Add Value to your Share Portfolio


Download eBook | Samso Insights
Download eBook

If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.



Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.


bottom of page